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Spinal muscular atrophy (SMA) is a common autosomal recessive neuromuscular disorder that is cur-
rently incurable. SMA is caused by decreased levels of the survival motor neuron protein (SMN), as a
result of loss or mutation of SMN1. Although the SMN1 homolog SMN2 also produces some SMN protein,
it does not fully compensate for the loss or dysfunction of SMN1. Salbutamol, a β2-adrenergic receptor
agonist and well-known bronchodilator used in asthma patients, has recently been shown to ameliorate
symptoms in SMA patients. However, the precise mechanism of salbutamol action is unclear. We treated
SMA ﬁbroblast cells lacking SMN1 and HeLa cells with salbutamol and analyzed SMN2 mRNA and SMN
protein levels in SMA ﬁbroblasts, and changes in SMN protein ubiquitination in HeLa cells. Salbutamol
increased SMN protein levels in a dose-dependent manner in SMA ﬁbroblast cells lacking SMN1, though
no signiﬁcant changes in SMN2 mRNA levels were observed. Notably, the salbutamol-induced increase in
SMN was blocked by a protein kinase A (PKA) inhibitor and deubiquitinase inhibitor, respectively. Co-
immunoprecipitation assay using HeLa cells showed that ubiquitinated SMN levels decreased in the
presence of salbutamol, suggesting that salbutamol inhibited ubiquitination. The results of this study
suggest that salbutamol may increase SMN protein levels in SMA by inhibiting ubiquitin-mediated SMN
degradation via activating β2-adrenergic receptor-PKA pathways.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Spinal muscular atrophy (SMA) is a common autosomal re-
cessive neuromuscular disorder characterized by degeneration of
α-motor neurons in the spinal cord, leading to muscular atrophy of
the limbs and trunk. Unfortunately, SMA remains incurable. SMA is
classiﬁed into three groups, depending on the age of onset and the
achievement of motor milestones: SMA type I (Werdnig–Hoffman
disease; severe form), SMA type II (intermediate form) and SMA
type III (Kugelberg–Welander disease; mild form) [1].B.V. This is an open access article u
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io).The survival motor neuron genes SMN1 (telomeric SMN) and
SMN2 (centromeric SMN) have been identiﬁed as candidate SMA-
causing genes at chromosome 5q11.2–13.3 [2]. SMN1 and SMN2
are largely identical, but nucleotide þ6 in the coding region is a C
in SMN1 and a T in SMN2, though these are synonymous and do
not result in an amino acid change. However, SMN1, but not SMN2,
is now recognized as an SMA-causing gene, because SMN1 is
completely deleted in more than 90% of SMA patients [3] and
deleteriously mutated in the remaining patients [4].
Although the SMN1 homolog SMN2 encodes the same protein,
it does not fully compensate for the loss or dysfunction of SMN1.
The C-to-T transition alters the splicing pattern in SMN2 exon 7
[5,6]. SMN1 exclusively produces full-length (FL) SMN1 transcripts,
while SMN2 produces about 90% of exon 7-lacking (Δ7) SMN2
transcripts and only about 10% of FL-SMN2 transcript [7]. The low
levels of functional SMN protein produced by the FL-SMN2nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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SMN1-generated SMN protein. However, SMN2 is never lacking in
SMA patients [2] and its copy number correlates inversely with
disease severity; a higher SMN2 copy number may ameliorate the
clinical phenotype [8]. SMN2 may thus partly compensate for the
loss of SMN1 by modifying disease severity through the production
of functional SMN protein.
Current treatment strategies for SMA have focused on en-
hanced production of SMN from SMN2, including by activation of
SMN2 transcription and by modulation of exon 7 skipping [9].
Valproic acid, a histone deacetylase inhibitor, is the representative
drug for the ﬁrst of these strategies [10,11], while ISIS-SMNRx, an
antisense oligonucleotide masking a splicing suppressor in the
SMN2 intron 7 [12], is used for the second strategy.
However, the β2-adrenergic receptor agonist, salbutamol,
which is widely used as a bronchodilator in asthma patients, has
recently been reported to alleviate symptoms in SMA patients [13–
15], and Angelozzi et al. reported that salbutamol increased SMN
protein levels in SMA ﬁbroblast cells [16]. However, the mechan-
ism whereby salbutamol increases SMN protein levels remains
unclear. Angelozzi et al. suggested that salbutamol may increase
SMN levels by increasing SMN2 transcripts [16]. Tiziano et al. also
reported a signiﬁcant and constant increase in FL-SMN2 transcripts
in peripheral blood cells from SMA patients treated with salbuta-
mol [17]. However, Burnett et al. found that the SMN complex was
stabilized by activation of cyclic AMP (cAMP) and protein kinase A
(PKA), with consequent increases in SMN protein levels [18],
suggesting that salbutamol enhances SMN protein levels through
other pathways.
To clarify the mechanism responsible for the salbutamol-in-
duced increase in SMN protein levels, we treated SMA ﬁbroblast
cells lacking SMN1 and HeLa cells with salbutamol. We analyzed
SMN2 transcript and SMN protein levels in SMA ﬁbroblast cells,
and assessed the effects of salbutamol on SMN protein ubiquiti-
nation in HeLa cells.2. Materials and methods
2.1. Establishment of ﬁbroblast cells and cell cultures
Skin tissue for primary culture of ﬁbroblast cells was obtained
from a 13-year-old girl with SMA type 3, who had complete ab-
sence of SMN1 but carried three copies of SMN2. This study was
approved by the ethical committee of Kobe University, and in-
formed consent was obtained from the patient and her parents.
Alteration of SMN2 transcript and SMN protein levels were
investigated in SMA ﬁbroblast cells. The ﬁbroblast cells were
maintained in Dulbecco's modiﬁed Eagle's medium (DMEM)-low
glucose (Sigma-Aldrich, St. Louis, MO, USA) containing 10,000 U/
ml penicillin, 10 mg/ml streptomycin, 25 mg/ml amphotericin B
(Fungizone; Life Technologies, Carlsbad, CA, USA), and 10% heat-
inactivated fetal bovine serum (FBS; Sigma-Aldrich) in a 5% hu-
midiﬁed CO2 atmosphere at 37 °C. Fibroblast cells were analyzed
at 5–15 passages.
Ubiquitinated SMN was investigated in HeLa cells carrying two
copies of SMN1 and two copies of SMN2. HeLa cells were used for
co-immunoprecipitation (co-IP) experiments because of their
ability to produce more SMN protein than ﬁbroblast cells. HeLa
cells were maintained in DMEM–high glucose (Sigma-Aldrich)
containing 10,000 U/ml penicillin, 10,000 mg/ml streptomycin,
25 mg/mL amphotericin B (Life Technologies) and 8% heat-in-
activated FBS in a 5% CO2 atmosphere at 37 °C.2.2. Salbutamol treatment of ﬁbroblast cells
Salbutamol sulfate was purchased from Wako Pure Chemical
Industries, Ltd. (Osaka, Japan). Salbutamol solution 1 mM was
freshly prepared in phosphate-buffered saline (PBS) before each
use. To clarify if SMN2 transcript or SMN protein was induced by
salbutamol, SMA ﬁbroblast cells were incubated with ﬁnal con-
centrations of salbutamol sulfate of 0.005, 0.05, and 0.5 mM, re-
spectively. SMN2 transcript levels were measured at 0 m (pre-
treatment), 5 m, 15 m, 30 m, 1 h, 2 h, 4 h, 8 h, 12 h, 24 h and 36 h.
SMN protein levels were measured at 0 h (pretreatment), 1 h, 6 h,
8 h, 12 h, 24 h and 36 h.
The mechanism whereby salbutamol increased SMN protein
levels was further investigated by adding PKA inhibitor 14–22
amide cell-permeable, myristoylated (Calbiochem; Darmstadt,
Germany) (ﬁnal concentration; 1 mM) and DUB inhibitor PR-619
(LifeSensors, Malvern, PA, USA) (ﬁnal concentration; 10 mM), re-
spectively, to SMA ﬁbroblast cells with salbutamol (ﬁnal con-
centration; 0.5 mM), and incubating for 36 h.
2.3. Reverse-transcription PCR analysis of salbutamol-treated ﬁbro-
blast cells
Total RNA extraction and cDNA synthesis were conducted as
described previously [19]. To evaluate transcript levels of the SMN
genes, we ampliﬁed FL- and Δ7-SMN transcripts from cDNA of
SMA ﬁbroblast cells. Real-time quantitative reverse-transcription
PCR was performed using a LightCycler 1.5 (Roche Diagnostics
GmbH, Mannheim, Germany). cDNA ampliﬁcation was carried out
using FastStart DNA Master SYBR Green I (Roche Diagnostics
GmbH).
The cDNA fragments containing exons 7 and 8 and exons 5 and
6/8 (ﬂanking sequences of the exon boundary) represented FL- and
Δ7-SMN, respectively. Glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) was used as an endogenous reference gene
and the relative denominator for the SMN2 transcript. The amount
of SMN2 transcript (relative to GAPDH) at 0 min (pretreatment
time) was normalized to 1.0 in each dose group. The primer se-
quences and PCR conditions are listed in Table 1 (Supplementary
material).
2.4. Western blotting analysis of salbutamol-treated ﬁbroblast cells
Protein samples were prepared as described previously [19].
The protein samples were homogenized and subjected to western
blotting. Brieﬂy, the homogenized protein samples were electro-
phoresed by 10% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred to a polyvinylidene
diﬂuoride (PVDF) membrane (GE Healthcare, Cleveland, OH, USA)
using a Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad, CA, USA).
Immunostaining of the membranes was performed using the iBind
Western System (Life Technologies). The following combinations
of antibodies were used to detect SMN and tubulin: mouse anti-
SMN antibody (BD Transduction Laboratories, Franklin Lakes, NJ,
USA), ECL horseradish peroxidase (HP)-linked sheep anti-mouse
IgG (GE Healthcare), rabbit polyclonal anti-beta tubulin antibody
(Abcam, Cambridge, MA, USA), and ECL HP-linked donkey anti-
rabbit IgG (GE Healthcare).
Chemiluminescent signals produced using Amersham ECL Plus
Western Blotting Detection Reagents (GE Healthcare) were de-
tected using a luminescent image analyzer LAS-3000 mini (Fuji-
ﬁlm, Tokyo, Japan). The signal intensity of the membrane was
determined using Multi Gauge Version 3.0 software (Fujiﬁlm).
Western blotting experiments and signal-intensity analysis were
repeated at least three times. Tubulin was used as an endogenous
reference protein and as the relative denominator for the SMN
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Fig. 1. FL- and Δ7-SMN2 transcript expression in salbutamol-treated SMA ﬁbroblast cells. FL- and Δ7-SMN2 transcript levels were unaffected by different salbutamol
concentrations and exposure time up to 36 h. Salbutamol concentrations used in this study were 0.005, 0.05 and 0.5 mM. Measurement time points were 0 m, 5 m, 15 m,
30 m, 1 h, 2 h, 4 h, 8 h, 12 h, 24 h and 36 h. (A) Dose-response curve and (B) time-course curve.
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ment time) in each dose group were normalized to 1.0.
2.5. Co-IP experiments of SMN complex in HeLa cells
We assessed the effect of salbutamol on SMN ubiquitination by
co-IP experiments using HeLa cells. Our preliminary experiments
showed that SMN expression level of HeLa cells was greater than that
of human ﬁbroblasts (data not shown). In addition, the tolerated dose
of salbutamol in HeLa cells was higher than that in ﬁbroblast cells
(data not shown). Thus, we used HeLa cells for co-IP experiment and
administered a higher dose of salbutamol to the HeLa cells.
HeLa cells were incubated with salbutamol sulfate (ﬁnal con-
centration: 20 mM) for 24 h in the presence or absence of the
proteasome inhibitor, MG132 (Wako Pure Chemical Industries,
Ltd.) (ﬁnal concentration; 5 mM).
Prior to co-IP, the cells were lysed in immunoprecipitation
buffer (50 mM Tris–HCl pH 7.2, 100 mM NaCl, 5 mM EDTA pH 8.0,
2% Triton-X) and 2 mM phenylmethanesulfonyl ﬂuoride (Sigma-
Aldrich) then sonicated for 7 s. After overnight incubation at
80 °C, the lysate was incubated with anti-SMN at 4 °C on a
slowly rotating shaker for 2 h. The co-immunoprecipitate (SMN
complex) was then isolated by adding protein G PLUS-Agarose
beads (Santa Cruz Biotechnology, Inc., TX, USA). The beads were
washed twice with PBS and once with the same im-
munoprecipitation buffer before adding to the lysate. After an
additional 2 h rotation at 4 °C with the beads, the co-im-
munoprecipitate was collected by centrifugation, washed twice
with PBS, and once with immunoprecipitation buffer. The pellet
was eluted by boiling in 3 NuPAGE LDS Sample Buffer (Life
Technologies Corporation) with β-mercaptoethanol.
The eluted co-IP samples were electrophoresed by 10% SDS-
PAGE and blotted to PVDF membranes. Immunostaining was per-
formed using iBind Western System (Life Technologies). Ubiquiti-
nated SMN was detected using a mouse monoclonal anti-ubiquitin
antibody (Sigma-Aldrich), mouse anti-SMN antibody, and ECL HP-
linked sheep anti-mouse IgG. The chemiluminescent signal wasdetermined as described above. The amount of ubiqtitinated SMN
at the mock status (not treated with salbutamol) was normalized
to 1.0 in each MG132 group (in the presence or absence of MG132).
The experiments were repeated four times.
2.6. Statistical analysis
Statistical analysis was performed using Microsoft Excel with
the add-in software Statcel3 (OMS Ltd., Tokyo, Japan). SMN2
transcript amounts were analyzed by two-way analysis of variance
(ANOVA) with one observation per cell. Differences in SMN protein
levels were analyzed by repeated measures two-way and one-way
ANOVAs followed by post-hoc analyses with Tukey–Kramer's
multiple-comparison test. Ubiquitinated SMN protein amounts
were compared by Mann–Whitney test. p Valueso0.05 were
considered statistically signiﬁcant.3. Results
3.1. Salbutamol did not increase SMN2 transcript levels
To test the possibility that salbutamol regulated the expression
of SMN2 transcripts in SMA ﬁbroblast cells, we assayed SMN2
transcript isoform levels using real-time quantitative PCR after
treatment of cells with various concentrations of salbutamol
(0.005, 0.05 and 0.5 mM) for time periods up to 36 h. The dose–
response curve showed no signiﬁcant differences in FL- and Δ7-
SMN2 transcript levels in relation to salbutamol concentration
(Fig. 1A). The time-course curve also showed no signiﬁcant chan-
ges in FL- and Δ7-SMN2 transcript levels throughout the ob-
servation period (Fig. 1B).
3.2. Salbutamol increased SMN protein levels
SMN protein levels were determined by western blotting at 0 h
(pretreatment), 1 h, 6 h, 8 h, 12 h, 24 h and 36 h in the presence of
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Fig. 2. SMN protein expression in salbutamol-treated SMA ﬁbroblast cells. Salbutamol concentrations used in this study were 0.005, 0.05 and 0.5 mM. Measurement time
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SMN protein levels peaked at 12 h (with 0.05 mM salbutamol) or
24 h (with 0.005 and 0.5 mM salbutamol). The highest SMN protein
levels with 0.005, 0.05, and 0.5 mM of salbutamol were 2.0-, 2.6-
and 3.5-fold basal levels, respectively.
Salbutamol increased SMN protein levels in dose- and time-
dependent manners. Two-way ANOVA showed signiﬁcant differ-
ences for dose (0.005, 0.05, and 0.5 mM) (po0.01) and time point
(po0.01), but no signiﬁcant interaction between dose and time
point. Post hoc analysis with Tukey–Kramer's multiple-comparison
tests showed signiﬁcant differences between 0.005 and 0.5 mM
and between 0.05 and 0.5 mM, and between 0 h and 12 h, 0 h and
24 h, and 0 h and 36 h.
3.3. PKA inhibitor blocked salbutamol-induced increase in SMN
protein
β2-adrenergic receptor binding to salbutamol activates PKA,
which affects the downstream targets of the signaling pathways.
To clarify the role of PKA pathways in the salbutamol-induced
increase in SMN protein, we added a PKA inhibitor, 14–22 amide
cell-permeable, myristoylated (ﬁnal concentration: 1 mM), to the
ﬁbroblast cell culture medium together with salbutamol (ﬁnal
concentration: 0.5 mM) (Fig. 2C).
The PKA inhibitor completely repressed the salbutamol-in-
duced increase in SMN. Two-way ANOVA showed signiﬁcant dif-
ferences in SMN protein levels in relation to PKA inhibitor (pre-
sence or absence) (po0.01), time point (po0.01), and PKA in-
hibitor time point interaction (po0.05). Post hoc analysis with
Tukey–Kramer's multiple-comparison test showed signiﬁcant dif-
ferences between PKA inhibitor (presence) and PKA inhibitor
(absence), and between 0 h and 12 h, and 0 h and 24 h. One-way
ANOVA for PKA inhibitor (presence) followed by post hoc analysiswith Tukey–Kramer's multiple-comparison test showed no sig-
niﬁcant increase in SMN protein levels during the observation
period. These results suggested that the salbutamol-induced in-
crease in SMN may be regulated by PKA pathways.
3.4. Salbutamol inhibited the ubiquitination of SMN protein
We investigated the effect of salbutamol on SMN ubiquitination
by performing co-IP experiments in HeLa cells. Salbutamol re-
duced SMN ubiquitination in the presence or absence of the pro-
teasome inhibitor MG132 (Fig. 3A and B). Quantiﬁcation analysis
showed that salbutamol signiﬁcantly reduced SMN ubiquitination
(Mann–Whitney test, po0.05). The mean ubiquitinated SMN
amount decreased by 20–30 percent after salbutamol treatment
(Fig. 3B). These ﬁndings suggested that salbutamol may inhibit
binding of ubiquitin to SMN.
3.5. Deubiquitinase inhibitor hampered the salbutamol-induced in-
crease in SMN protein
We hypothesized that salbutamol may inhibit ubiquitination
during the process of SMN protein degradation. To test this hy-
pothesis, we added a DUB inhibitor (PR-619, which facilitates
ubiquitination) to the ﬁbroblast cell culture medium (ﬁnal con-
centration; 10 mM), together with salbutamol (ﬁnal concentration;
0.5 mM) (Fig. 4).
The DUB inhibitor partially repressed the salbutamol-induced
increase in SMN. Two-way ANOVA showed signiﬁcant differences
in SMN protein levels in relation to the DUB inhibitor (presence or
absence) (po0.01) and time point (po0.01), and DUB in-
hibitor time point interaction (po0.05). Post hoc analysis with
Tukey–Kramer's multiple-comparison test showed signiﬁcant dif-
ferences between DUB inhibitor presence and absence, and
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Fig. 3. Co-immunoprecipitation (co-IP) experiments in HeLa cells. Ubiquitinated
SMN protein was determined by co-IP using anti-SMN antibody. (A) Ubiquitinated
SMN extracted by co-IP. HeLa cells were incubated with salbutamol sulfate (20 mM)
for 24 h in the presence or absence of the proteasome inhibitor, MG132 (5 mM).
SMN ubiquitination was reduced in HeLa cells treated with salbutamol, in the
presence or absence of MG132. (B) Quantiﬁcation of ubiquitinated SMN levels. The
amount of ubiquitinated SMN at the mock status (not treated with salbutamol) was
normalized to 1.0 in each MG132 group (in the presence or absence of MG132). The
mean ubiquitinated SMN amount decreased by 20–30 percent after salbutamol
treatment.
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inhibitor (presence) followed by post hoc analysis with Tukey–
Kramer's multiple-comparison test showed a signiﬁcant increase
in SMN protein levels between 0 h and 12 h, 0 h and 24 h, and 0 h
and 36 h, suggesting that the repression was incomplete. These
results suggested that the salbutamol-induced increase of SMN
may be related to SMN ubiquitination.4. Discussion
In this study, we conﬁrmed that salbutamol increased SMN
protein levels in SMA ﬁbroblast cells in accord with Angelozzi et al.
[16]. However, Angelozzi et al. also found that FL-SMN2 transcript
levels were increased by salbutamol, suggesting that salbutamol
increased the production of SMN from SMN2. In contrast, we
found no signiﬁcant time- or dose-related changes in FL-SMN2 orΔ7-SMN2 transcript levels in response to salbutamol. This appar-
ent discrepancy in terms of response of SMN2 transcripts to sal-
butamol may be attributable to the use of cells from a non-tran-
script-responder to salbutamol.
β2-adrenergic receptor agonists, including salbutamol, trigger
elevation of cAMP and activate some PKA-signaling pathways. To
examine the role of PKA-signaling pathways in our patient, we
added a PKA inhibitor to the ﬁbroblast cell culture medium, to-
gether with salbutamol, and found that the salbutamol-induced
increase in SMN protein was completely blocked. This strongly
suggested that salbutamol increased SMN protein levels via PKA-
signaling pathways.
One of the PKA-signaling pathways may involve cAMP-re-
sponse-element-binding (CREB) protein and cAMP-response ele-
ments (CREs) in gene promoters. The sequences of SMN1/2 pro-
moter regions also includes CREs [20,21]. The SMA ﬁbroblast cells
of Angelozzi et al. showed that salbutamol increased the produc-
tion of FL-SMN2 transcript produced by SMN2 promoter activated
through the PKA-signaling pathway. However, in some cases such
as our patient, the effect of PKA signaling pathways on SMN2
promoter activation may be limited. Those patients may have
some defects in the PKA pathway involving, CREB protein and
CREs in the SMN2 promoter [22], and may not increase SMN2
transcripts. Our study suggested that there may be other me-
chanisms of salbutamol than activating the SMN2 promoter.
On the other hand, SMN protein is known to be degraded by
the ubiquitin/proteasome system [23]. We conﬁrmed the interac-
tion between SMN and ubiquitin by co-IP with an anti-SMN an-
tibody in HeLa cells. Then, we examined SMN ubiquitination levels
before and after salbutamol treatment, with or without the pro-
teasome inhibitor MG-132, and showed that salbutamol treatment
partially blocked ubiquitination of SMN. This ﬁnding suggested
that salbutamol inhibits ubiquitination of SMN, leading to inhibi-
tion of SMN degradation. To test this hypothesis, we added a DUB
inhibitor, PR-619, to the ﬁbroblast cells together with salbutamol,
and found that the salbutamol-induced increase in SMN protein
levels was blocked in the presence of the DUB inhibitor.
Our results raise the possibility that one of the PKA-signaling
pathways may phosphorylate SMN and inhibit the ubiquitination
of SMN. Phosphorylation by PKA-signaling pathway is known to
inhibit ubiquitination of some proteins, such as catenin [24]. Bur-
nett et al. has shown another possibility [18]. They demonstrated
that PKA-signaling pathways increased the amount of SMN and
non-SMN proteins (Gemin2, Gemin3 and Gemin5) in the SMN
complex, suggesting that SMN stability may also be inﬂuenced by
oligomerization and complex formation [18]. It may be summar-
ized that salbutamol may increase SMN and non-SMN proteins in
the SMN complex, facilitate and maintain SMN-complex forma-
tion, and affect SMN-complex function, thus promoting SMN-
complex stability and function.
Salbutamol alleviates the symptoms in SMA patients [13–15].
The beneﬁcial effects of salbutamol can be explained partly by
prevention of SMN protein degradation. Kwon et al. found that the
proteasome inhibitor bortezomib increased SMN protein levels in
cultured cells and in peripheral tissues of SMA model mice. Fur-
thermore, bortezomib improved motor function in SMN model
mice [25]. Prevention of SMN degradation may thus represent a
new treatment strategy for SMA.
This study was limited to the use of ﬁbroblast cells from only
one patient. Although salbutamol had no effect on SMN2 promoter
activation in this patient's ﬁbroblast cells, we were unable to de-
tect this phenomenon in other SMA patients. However, the ab-
sence of SMN2 promoter activation in our patient allowed us to
ﬁnd the effect of salbutamol on SMN protein stabilization. In this
study, we showed a new pathway of “salbutamol-PKA-X-in-
hibition of SMN ubiquitination” in one SMA subject. Further
N.I.F. Harahap et al. / Biochemistry and Biophysics Reports 4 (2015) 351–356356analyses using more SMA subjects are necessary to clarify the X
factors.
In conclusion, this study demonstrated that salbutamol may
increase SMN protein levels in SMA by inhibiting ubiquitin-
mediated SMN degradation via activating β2-adrenergic receptor-
PKA pathways. Prevention of SMN degradation may thus represent
a new strategy for the treatment of SMA, and a better under-
standing of the SMN-degradation mechanism may afford new
clues for the development of SMA therapeutics.Acknowledgments
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